NOV 07, 2017 10:00 AM PST

WEBINAR: Chimeric Antigen Receptors: From proof of concept to widely applicable clinical research solutions

SPONSORED BY: Miltenyi Biotec
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Translational R&D, Cell Biology, Lentigen Technology, Inc., a Miltenyi Biotec Company
    Biography
      Dr. Dina Schneider holds PhD in Pharmacology and Toxicology from Michigan State University. Her doctoral thesis focused on pathways of B cell activation and differentiation. Her post-doctoral work at the University of Michigan, Ann Arbor, focused on cellular immune responses to viral infections in airway inflammatory diseases. In 2011, Dr. Schneider transitioned to industry, where she contributed to numerous projects in synthetic immunology, immunotherapy, and chimeric antigen receptor (CAR) T cell-based therapy. Dr. Schneider leads the Cell Biology group at Lentigen Technology, Inc., a Miltenyi Biotec Company, in Gaithersburg, MD. Her group is focused on pre-clinical development of novel CAR-based therapies, and on the implementation of CliniMACS Prodigy® platform for preparation of cell-based therapeutics.

    Abstract:

    DATE: November 7, 2017 
    TIME: 10:00AM PST

    Chimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in phase I trials.  In most instances, lentivirus-based or a retrovirus-based gene vectors were used to introduce the therapeutic gene expression cassette into the genome of T lymphocytes.  The gene expression cassette is composed of an internal promoter and the CAR, created by splicing together of extracellular antigen-binding motifs, linker and transmembrane domains, and intracellular lymphocyte signaling domains.  This synthetic engineered receptor can be modified in a number of ways in order to further improve CAR T efficacy and safety.  We have found that the combination of two extracellular binding domains is possible, thus expanding the antigens targeted by a single CAR construct, and potentially providing a more effective barrier to the generation of antigen-escape variants. Making CAR-based immunotherapy broadly available to those in need, requires the ability to isolate, activate, transduce, and expand T cell or NK cell populations in a safe clinically-relevant platform.  The CliniMACS® Prodigy is a closed cell culture system that combines recent advances in lymphocyte isolation (using antibody-conjugated matrices), activation (using an anti-CD3/CD28 nanomatrix), and automated culture using optimized media and cytokines, into a single platform suitable for the introduction of therapeutic gene vectors, lymphocyte transduction, culture and expansion, and final formulation.  Using clinical-grade lentivirus-based gene vectors we have demonstrated the ability to produce CAR-expressing T cells.  The CliniMACS® Prodigy platform provides a standardized solution for broad application of CAR-based therapies in clinical studies.

     

    Learning Objectives:

    • Review critical aspects for creating CAR T cells
    • Review process of CAR-modified cell manufacturing

     


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 24, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    MAY 29, 2018 09:00 AM PDT
    C.E. CREDITS
    MAY 29, 2018 09:00 AM PDT
    Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    Loading Comments...